{"id":"eylea-solution-for-intravitreal-injection","safety":{"commonSideEffects":[{"rate":"25–30%","effect":"Conjunctival hemorrhage"},{"rate":"10–15%","effect":"Eye pain"},{"rate":"10–15%","effect":"Floaters"},{"rate":"5–10%","effect":"Intraocular pressure elevation"},{"rate":"0.1–0.5%","effect":"Endophthalmitis"},{"rate":"<1%","effect":"Retinal detachment"}]},"_chembl":null,"_fixedAt":"2026-03-30T16:21:41.712197","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Aflibercept is a soluble decoy receptor that acts as a VEGF trap, sequestering VEGF-A, VEGF-B, and PlGF in the vitreous. By preventing these growth factors from binding to their native receptors on endothelial cells, it reduces pathological neovascularization and vascular permeability in retinal diseases. This mechanism halts the progression of vision-threatening conditions driven by excessive angiogenesis.","oneSentence":"Eylea (aflibercept) binds to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:12:09.114Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"},{"name":"Macular edema following retinal vein occlusion"},{"name":"Diabetic macular edema"},{"name":"Diabetic retinopathy"}]},"_fixedFields":["pubmed(25)"],"trialDetails":[{"nctId":"NCT06470373","phase":"PHASE3","title":"A Phase 3 Clinical Trial to Compare RBS-001 to Eylea® in Subjects With Neovascular Age-Related Macular Degeneration","status":"NOT_YET_RECRUITING","sponsor":"Rophibio, Inc.","startDate":"2025-07","conditions":"Neovascular Age-related Macular Degeneration (nAMD)","enrollment":434},{"nctId":"NCT02434328","phase":"PHASE3","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 2","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2015-07-28","conditions":"Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":1048},{"nctId":"NCT02307682","phase":"PHASE3","title":"Efficacy and Safety of RTH258 Versus Aflibercept - Study 1","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2014-12-08","conditions":"Neovascular Age-Related Macular Degeneration, Choroidal Neovascularization","enrollment":1775},{"nctId":"NCT04200248","phase":"PHASE2","title":"A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Ribomic USA Inc","startDate":"2019-12-02","conditions":"Exudative Age-related Macular Degeneration","enrollment":94},{"nctId":"NCT03802630","phase":"PHASE3","title":"Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-07-02","conditions":"Branch Retinal Vein Occlusion","enrollment":450},{"nctId":"NCT03810313","phase":"PHASE3","title":"Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-07-03","conditions":"Central Retinal Vein Occlusion","enrollment":493},{"nctId":"NCT03468296","phase":"PHASE4","title":"Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept","status":"UNKNOWN","sponsor":"Tennessee Retina","startDate":"2018-04","conditions":"Neovascular Age-related Macular Degeneration","enrollment":22},{"nctId":"NCT02401945","phase":"PHASE2","title":"A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2015-04","conditions":"Age-Related Macular Degeneration","enrollment":16},{"nctId":"NCT01796964","phase":"PHASE2","title":"Efficacy and Safety Study of ESBA1008 Versus EYLEA®","status":"COMPLETED","sponsor":"Alcon Research","startDate":"2013-03","conditions":"Exudative Age-Related Macular Degeneration","enrollment":173}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"recentPublications":[{"date":"2026","pmid":"41804317","title":"Measurement of Acute Intraocular Pressure Elevation Immediately After Intravitreal Anti-VEGF Injection and Analysis of Prefilled Syringe Accuracy.","journal":"Clinical ophthalmology (Auckland, N.Z.)"},{"date":"2026 Jan","pmid":"41316698","title":"Supramolecular Self-Assembled Multivalent Anti-VEGF Protein Nanospheres for Prolonged Ocular Retention.","journal":"Small (Weinheim an der Bergstrasse, Germany)"},{"date":"2025","pmid":"41282458","title":"Novel Needle for Intravitreal Injections Does Not Affect Biological Activity of Anti-VEGF Drugs.","journal":"Clinical ophthalmology (Auckland, N.Z.)"},{"date":"2026 Mar","pmid":"41247473","title":"Intravitreal injection delivered volume under different environmental and training conditions.","journal":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"},{"date":"2025 Nov","pmid":"40965569","title":"Investigating the feasibility of selective anti-VEGF delivery to the retina using a microinvasive approach.","journal":"Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Eylea® Solution for intravitreal injection","genericName":"Eylea® Solution for intravitreal injection","companyName":"Rophibio, Inc.","companyId":"rophibio-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eylea (aflibercept) binds to vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit abnormal blood vessel growth in the eye. Used for Neovascular (wet) age-related macular degeneration, Macular edema following retinal vein occlusion, Diabetic macular edema.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}